Income StatementBalance SheetCash FlowSegments
Vertex Pharmaceuticals logo

Vertex Pharmaceuticals Cash Flow Statement

Operating, investing, and financing cash movements

Vertex Pharmaceuticals generated $4.2B in operating cash flow over the trailing twelve months. After $530.3M in capital expenditures, free cash flow was $3.7B. Free cash flow increased 8.4% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$4.2BNet Cash From Investing (TTM)-$1.3BNet Cash From Financing (TTM)-$2.1BCapital Expenditures (TTM)$530.3MDepreciation And Amortization Cf (TTM)$217.3MNet Change In Cash (TTM)$819.5M
Latest FilingQ1 2026
Report Date2026-05-05
Market Cap$114.32B
P/E Ratio26.35
ROE24.2%

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Capital expenditures$92.6M$40.7M$145.7M$101.8M$149.4M$133.4M
Payment for (Proceeds from) Other Investing Activity—$5.3M———$0.0
Proceeds From Sale And Maturity Of Available For Sale Securities—$1.6B———$2.2B
Net cash from investing activities-$821.9M-$55.8M-$484.5M-$117.0M-$288.1M-$431.9M
Purchases of investments$2.2B$1.6B$2.2B$1.3B$1.2B$2.5B

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Change in accounts payable$8.4M$26.2M$7.6M-$35.3M$38.3M$35.6M
Change in accounts receivable—$169.6M$18.4M$59.9M$99.4M-$39.8M
Change in inventories$147.5M$167.1M$148.6M$131.1M$77.4M$97.7M
Change in other liabilities—$22.0M-$63.2M$83.9M$105.8M$23.1M
Depreciation and amortization$46.5M$48.4M$51.7M$54.0M$55.7M$55.9M
Net cash from operating activities—$818.9M$1.1B$1.2B$498.0M$1.4B
Net income—$646.3M$1.0B$1.1B$1.2B$1.0B
Goodwill and other intangible asset impairment charges—$379.0M———$0.0
Accrued expenses and other liabilities—$48.1M———$70.5M
Increase (Decrease) in Prepaid Expense and Other Assets—$28.1M———-$173.4M
Other Noncash Income (Expense)—-$39.2M———$5.0M
Stock-based compensation$167.8M$166.1M$167.3M$194.9M$157.6M$166.4M
Deferred rent expense-$87.2M-$127.7M-$127.7M-$127.7M-$127.7M-$65.3M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Proceeds from exercises of stock options and other stock issuances—$16.7M———$27.0M
Other, net—-$500.0K———-$400.0K
Net cash from financing activities-$391.3M-$680.4M-$349.2M-$1.2B-$77.2M-$538.8M
Repurchases of common stock$417.9M$426.1M$391.8M$1.1B$128.4M$336.9M
Taxes paid for net share settlement$7.3M$270.5M$5.9M$91.0M$2.5M$228.5M

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow—$778.2M$927.4M$1.1B$348.6M$1.3B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$47.3M$30.5M$57.2M-$4.1M$7.3M-$40.3M
Net increase (decrease) in cash-$675.9M$113.2M$296.6M-$34.2M$140.0M$417.1M

Supplemental

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Interest paid$2.7M$2.7M$3.5M$3.2M$3.0M$3.2M
Income Taxes Paid, Net—$184.4M———$82.3M
Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets$0.0$0.0$0.0$0.0$0.0—